Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer

Thyroid

Volumn 24, Issue 9, 2014, Pages 1329-1340

  Lacouture, Mario E ^a   Ciccolini, Kathryn ^a   Kloos, Richard T ^b   Agulnik, Mark ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Veracyte Inc   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; ANTIHISTAMINIC AGENT; CABOZANTINIB; CETUXIMAB; CLOBETASOL; CORTICOSTEROID; DEXAMETHASONE; DOXYCYCLINE; EMOLLIENT AGENT; LANOLIN ALCOHOL; LIDOCAINE; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SALICYLIC ACID; SORAFENIB; STEROID; SUNITINIB; SUNSCREEN; UNCLASSIFIED DRUG; VANDETANIB; VANICREAM; ANTINEOPLASTIC AGENT;

ACNE; ALGORITHM; ALOPECIA; CANCER PAIN; DERMATITIS; DERMATOLOGIST; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SAFETY; DRY SKIN; ERYTHEMA; HUMAN; HUMIDIFIER; HYPERKERATOSIS; INTERDISCIPLINARY COMMUNICATION; LOTION; MEDICAL SPECIALIST; METASTASIS; MOLECULARLY TARGETED THERAPY; NAIL DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT REFERRAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SKIN COLOR; SKIN DEFECT; SKIN DISEASE; SKIN MANIFESTATION; STOMATITIS; THYROID CANCER; CARCINOMA, MEDULLARY; CHEMICALLY INDUCED; THYROID NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; HUMANS; SKIN DISEASES; THYROID NEOPLASMS;

EID: 84907064730     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0700     Document Type: Review

References (71)

1. Siegel R, Naishadham D, Jemal A 2013 Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
2. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma v2.2013. Available at www.nccn.org/professionals/ physician-gls/pdf/thyroid.pdf (accessed August 21, 2013).
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648. (Pubitemid 29019586)
4. Roman S, Lin R, Sosa JA 2006 Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142. (Pubitemid 44665646)
5. Lodish MB, Stratakis CA 2008 RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer: molecular genetics and therapeutic advances. Expert Rev Anticancer Ther 8:625-632. (Pubitemid 351818356)
6. Landa I, Robledo M 2011 Association studies in thyroid cancer susceptibility: are we on the right track? J Mol Endocrinol 47:R43-R58.
7. Scollo C, Baudin E, Travagli J-P, Caillou B, Bellon N, Leboulleux S, Schlumberger M 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070-2075. (Pubitemid 36549878)
8. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612.
9. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290. (Pubitemid 36025251)
10. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655.
11. Hart CD, De Boer RH 2013 Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther 6:1-7.
12. Cometriq [package insert] 2012 South San Francisco, CA: Exelixis, Inc.
13. Caprelsa [package insert] 2013 Wilmington, DE: AstraZeneca Pharmaceuticals LP.
14. European Medicines Agency approves COMETRIQ. Available at www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002640/ human-med-001726.jsp (accessed March 30, 2014).
15. Sherman SI 2011 Targeted therapies for thyroid tumors. Mod Pathol 24:S44-S52.
16. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664-2671.
17. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772.
18. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134-141.
19. Schoffski P, Elisei R, Müller S, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Niederle B, Cohen EEW, Wirth LJ, Ali HY, Hessel C, Yaron Y, Ball DW, Nelkin B, Sherman SI, Schlumberger M for the EXAM Study Group 2012 An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline [abstract]. J Clin Oncol 30:Abstract 5508.
20. De Souza JA, Busaidy N, Zimrin A, Seiwert TY, Villaflor VM, Poluru KB, Reddy PL, Nam J, Vokes EE, Cohen EE 2010 Phase II trial of sunitinib in medullary thyroid cancer (MTC) [abstract]. J Clin Oncol 28:Abstract 5504.
21. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330.
22. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856. (Pubitemid 23216611)
23. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460. (Pubitemid 23179393)
24. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
25. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SAJr, Goodfellow PJ, Donis-KellerH1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91:1579-1583.
26. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG 1996 Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44:249-257. (Pubitemid 26063401)
27. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682-687. (Pubitemid 351398539)
28. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL 2010 Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20:863-871.
29. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976.
30. Rodriguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, Leskela S, Leandro-Garcia LJ, Lopez-Jimenez E, Leton R, Cascon A, Lerma E, Martin MC, Carralero MC, Mauricio D, Cigudosa JC, Matias-Guiu X, Robledo M 2010 Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 17:7-16.
31. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579.
32. Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, DiRenzo MF 2000 Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 11:19-30. (Pubitemid 30307941)
33. Downward J 2003 Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22. (Pubitemid 37328883)
34. Gomez K, Varghese, J, Jimenez, C 2011 Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res 2011:815-826.
35. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW 2013 Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 98:E364-E369.
36. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP 2008 Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-1011.
37. Bianchini D, Jayanth A, Chua YJ, Cunningham D 2008 Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin Colorectal Cancer 7:33-43. (Pubitemid 351252449)
38. Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME 2011 Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 50:129-146.
39. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN 2009 Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer 10:106-111.
40. National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0. Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-8.5x11.pdf (accessed April 3, 2014).
41. Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME 2012 Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 97:1125-1133.
42. Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, Mateus C, Tomasic G, Wechsler J, Schlumberger M, Robert C 2012 A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 148:1418-1420.
43. Sutent [package insert] 2013 New York, NY: Pfizer, Inc.
44. Nexavar [package insert] 2013 Wayne, NJ: Bayer Health-Care Pharmaceuticals, Inc.
45. Wagner LI, Lacouture ME 2007 Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21:34-36.
46. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME 2010 Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116:3916-3923.
47. Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taieb C 2011 HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16:1469-1478.
48. Dest VM 2009 Systemic therapy-induced skin reactions. In: Haas M, Moore-Higgs GJ (eds) Principles of Skin Care and the Oncology Patient. Pittsburgh, PA: Oncology Nursing Society.
49. Witt ME, Young M 2009 Common drug reactions with cutaneous manifestations. In: Haas M, Moore-Higgs GJ (eds) Principles of Skin Care and the Oncology Patient. Pittsburgh, PA: Oncology Nursing Society.
50. Johannsen LL 2005 Skin assessment. Dermatol Nurs 17:165-166.
51. Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S 2009 NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Cancer Netw 7:5-21.
52. Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA, MASCC Skin Toxicity Study Group 2011 Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079-1095.
53. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ 2011 Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol 23:343-351.
54. Lipworth AD, Robert C, Zhu AX 2009 Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77:257-271.
55. Balagula Y, Lacouture ME, Cotliar JA 2010 Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 8:149-161.
56. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M 2010 Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351-1357.
57. Scope A, Agero ALC, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC 2007 Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390-5396. (Pubitemid 350232214)
58. Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, Song T, Zhou W, Wang H, Yang W, Wang X, Yang Y, Shi L, Bai Y, Ye S-L 2012 A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma [abstract]. J Clin Oncol 30:Abstract 4008.
59. de Oliveira MA, Martins e Martins F, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS 2011 Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 47:998-1003.
60. Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, Treister N 2013 A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 49:293-298.
61. Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, Papadopoulou E, Sonis S 2013 Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol 116:e110-e116.
62. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME 2007 Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610-621. (Pubitemid 350012125)
63. Eaby B, Culkin A, Lacouture ME 2008 An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 12:283-290.
64. Memorial Sloan-Kettering Cancer Center. General guidelines to care for your dry skin. Available at www2.mskcc.org/patient-education/-assets/downloads- english/131.pdf (accessed April 3, 2014).
65. Schneider J 2002 The teaspoon rule of applying sunscreen. Arch Dermatol 138:838-839.
66. Lindblad AK, Kjellgren KI, Ring L, Maroti M, Serup J 2006 The role of dermatologists, nurses and pharmacists in chronic dermatological treatment: patient and provider views and experiences. Acta Derm Venereol 86: 202-208. (Pubitemid 43875203)
67. Gandhi M, Oishi K, Zubal B, Lacouture ME 2010 Unanticipated toxicities from anticancer therapies: survivors'perspectives. Support Care Cancer 18:1461-1468.
68. Helgeson VS, Cohen S 1996 Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Health Psychol 15:135-148. (Pubitemid 126468487)
69. White KJ, Roydhouse JK, Scott K 2011 Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment. Clin J Oncol Nurs 15:88-96.
70. Oishi K 2008 Clinical approaches to minimize rash associated with EGFR inhibitors. Oncol Nurs Forum 35: 103-111.
71. Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME 2012 Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 23:2103-2108.